[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Olistic Research Labs S.L.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100630160","efficacy-and-safety-of-a-drinkable-nutraceutical-for-hair-loss-in-patients-using-glp-1gip-receptor-agonists-100630160",false,"NCT07484061","Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1\u002FGIP Receptor Agonists","Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1\u002FGIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.","Inclusion Criteria:\n\n* Female gender.\n* Age \\>35 years.\n* Initiation of treatment with a GLP-1\u002FGIP agonist, or treatment duration \\\u003C 3 months, as per routine clinical practice in the endocrinology clinic.\n* Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.\n* Additional criteria to be included by the client.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.\n* Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.\n* Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).\n* Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.\n* Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.\n* Women who have used anti-hair loss products within the last 3 months.\n* Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).\n* Women who have undergone hair transplantation within the 18 months prior to study initiation.\n* Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.\n* Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.\n* Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.\n* Additional exclusion criteria to be specified by the sponsor.\n* Any condition that, in the investigator's opinion, makes participation in the study inappropriate.","FEMALE","35 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1\u002FGIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.",[26],"Telogen Effluvium","RECRUITING","2026-03-19",{"date":30,"type":31},"2026-03-23","ACTUAL",{"date":33,"type":31},"2026-03-16",{"date":35,"type":20},"2026-10-31",{"name":37,"class":38},"Olistic Research Labs S.L.","INDUSTRY",""]